Press Releases April 28, 2026 06:30 AM

Bilibili Inc. to Report First Quarter 2026 Financial Results on Tuesday, May 19, 2026

Bilibili Inc. to announce Q1 2026 financial results on May 19, 2026, with earnings call and webcast events planned.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
BILI

Bilibili Inc., a leading Chinese video community platform, will report its unaudited Q1 2026 financial results on May 19, 2026, before U.S. market open. Management will hold an earnings conference call and webcast for investors and media. Bilibili continues to focus on serving young generations in China with diverse video content and interactive features like bullet chatting.

Bilibili Inc. to Report First Quarter 2026 Financial Results on Tuesday, May 19, 2026
BILI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Bilibili will report Q1 2026 financial results on May 19, 2026 before U.S. market open.
  • Management will hold a conference call and live webcast for earnings discussion and Q&A.
  • Bilibili is a leading Chinese video community platform targeting young generations with interactive content features such as bullet chatting.

SHANGHAI, April 28, 2026 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it will report its first quarter 2026 unaudited financial results on Tuesday, May 19, 2026, before the open of U.S. markets.

The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 19, 2026 (8:00 PM Beijing/Hong Kong Time on May 19, 2026). Details for the conference call are as follows:

Event Title:Bilibili Inc. First Quarter 2026 Earnings Conference CallRegistration Link:https://register-conf.media-server.com/register/BI1530efabe5854ae9b543c742532a0334 

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers and a personal PIN, which will be used to join the conference call.

Additionally, a live webcast of the conference call will be available on the Company’s investor relations website at http://ir.bilibili.com, and a replay of the webcast will be available following the session.

About Bilibili Inc.

Bilibili is an iconic brand and a leading video community with a mission to enrich the everyday lives of young generations in China. Bilibili offers a wide array of video-based content with “All the Videos You Like” as its value proposition. Bilibili builds its community around aspiring users, high-quality content, talented content creators and the strong emotional bonds among them. Bilibili pioneered the “bullet chatting” feature, a live comment function that has transformed users’ viewing experience by displaying the thoughts and feelings of audience members viewing the same video. The Company has now become the welcoming home of diverse interests among young generations in China and a frontier for promoting Chinese culture around the world.

For more information, please visit: http://ir.bilibili.com.

For investor and media inquiries, please contact:

In China:

Bilibili Inc.
Juliet Yang
Tel: +86-21-2509-9255 Ext. 8523
E-mail: [email protected]

Piacente Financial Communications
Helen Wu
Tel: +86-10-6508-0677
E-mail: [email protected] 

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]


Risks

  • Financial results are unaudited at the time of the announcement, which may lead to future revisions impacting stock price.
  • Bilibili operates in a highly competitive and regulated video streaming sector in China, exposing it to regulatory risks and market competition.
  • The company’s growth depends heavily on user engagement and content creation which can be influenced by changing consumer preferences and internet regulations.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026